Spironolactone for Acne in Geriatric Patients (65+): Transition to Adult Care

What Is Spironolactone and Why Is It Used for Acne After 65?

Spironolactone is a synthetic aldosterone antagonist that also blocks androgen receptors in sebaceous glands, reducing sebum production and comedone formation. Dermatologists have prescribed it off-label for hormonal acne in women for decades, typically in younger reproductive-age populations, but a meaningful subset of patients either start or continue it past age 65. Late-onset acne in postmenopausal women is more common than widely assumed. One population-based analysis found acne prevalence of approximately 3 to 5% in women aged 41 to 50, with rates persisting into later decades for a subset driven by relative androgen excess after estrogen withdrawal [1].

When a patient who was well-controlled on spironolactone crosses into geriatric care, or when a 65+ patient presents with new hormonal acne, the prescribing clinician must weigh efficacy against a substantially different risk profile than exists in younger adults.

Mechanism Relevant to Acne

Spironolactone competitively inhibits dihydrotestosterone (DHT) binding at androgen receptors in pilosebaceous units. This reduces sebocyte proliferation and sebum output. At doses of 50 to 100 mg/day, sebum suppression is measurable within 4 to 6 weeks, and clinical acne reduction is typically apparent by week 8 to 12 [2].

Who Presents With Acne After 65?

Most cases involve postmenopausal women with relative androgen dominance. Testosterone clearance slows after menopause; SHBG levels may also drop, raising free androgen fractions. These patients often have comedonal and inflammatory lesions on the lower face and jaw, indistinguishable morphologically from the hormonal acne pattern seen at age 30 to 45. A serum DHEA-S and free testosterone measurement helps confirm the hormonal driver and justifies antiandrogen therapy.

Pharmacokinetics in the Geriatric Patient

Age changes every pharmacokinetic parameter that matters for spironolactone. Ignoring those changes is how adverse events occur.

Absorption and Distribution

Oral bioavailability of spironolactone is approximately 60 to 90% and is not substantially altered by age alone. However, reduced gastric acid production and slowed gastric emptying in older adults may shift the absorption curve. The volume of distribution changes as lean body mass falls and total body fat rises, altering the tissue distribution of lipophilic metabolites such as canrenone [3].

Hepatic Metabolism

Spironolactone is extensively metabolized in the liver to active metabolites, primarily canrenone and 7-alpha-thiomethylspironolactone. Hepatic blood flow and CYP enzyme activity both decline with age. In patients with even mild hepatic impairment, active metabolite accumulation can prolong the effective half-life from roughly 13 to 24 hours to considerably longer, increasing exposure without a corresponding dose increase [4].

Renal Clearance and the eGFR Threshold

This is the most clinically important consideration. Canrenone is renally cleared. In adults with an eGFR of 60 mL/min/1.73 m² or above, standard dosing applies. As eGFR falls below 45 mL/min/1.73 m², metabolite accumulation drives hyperkalemia risk up sharply. The FDA label for spironolactone states that its use is generally contraindicated in patients with significant impairment of renal excretory function [5]. For geriatric patients, who have a median eGFR roughly 20 to 30% lower than young adults simply due to age-related nephron loss, this threshold is reached far more often.

A patient who was tolerating spironolactone 100 mg/day at age 58 with an eGFR of 72 may have an eGFR of 52 at age 68 without any new renal disease. The dose that was safe at 58 may no longer be safe at 68.

Hyperkalemia: The Central Geriatric Safety Concern

Hyperkalemia is the adverse event most likely to cause serious harm in older patients on spironolactone.

Baseline Risk

Normal aging impairs the kidney's ability to excrete a potassium load by reducing aldosterone responsiveness and tubular secretory capacity. One large pharmacovigilance study of heart failure patients found that the risk of hyperkalemia-related hospitalization tripled in patients over 70 compared to those under 55 taking aldosterone antagonists at equivalent doses [6]. Acne patients are healthier than heart failure cohorts, but the renal physiology is the same.

Potassium-Elevating Drug Combinations

Geriatric patients carry a far heavier polypharmacy burden than younger adults. The average Medicare beneficiary fills prescriptions for 4 to 5 distinct drug classes per year [7]. The following combinations with spironolactone meaningfully raise hyperkalemia probability:

• ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan): concurrent use raises serum potassium by an additional 0.5 to 1.0 mEq/L on average
• NSAIDs (ibuprofen, naproxen): reduce renal prostaglandin synthesis, impairing potassium excretion
• Trimethoprim (in TMP-SMX): blocks ENaC channels in the distal nephron, acting pharmacodynamically like a potassium-sparing diuretic
• Potassium supplements and salt substitutes containing potassium chloride
• Heparin and low-molecular-weight heparin: suppress aldosterone synthesis

Every geriatric patient starting or continuing spironolactone for acne needs a full medication reconciliation before the first dose is written.

Monitoring Protocol for Patients 65+

Standard dermatology practice for younger adults often involves a baseline potassium check and then annual monitoring. That interval is not adequate for geriatric patients. The following schedule reflects recommendations from the American College of Cardiology / American Heart Association guidelines on aldosterone antagonist monitoring [8] adapted to the lower-risk acne indication:

1. Baseline: complete metabolic panel (CMP) and eGFR
2. Week 4: serum potassium and creatinine
3. Month 3: repeat CMP
4. Every 6 months thereafter if stable (every 3 months if eGFR <60 or potassium was 4.5 to 5.0 mEq/L at any prior check)

Withhold or discontinue spironolactone if potassium exceeds 5.0 mEq/L or eGFR falls below 30 mL/min/1.73 m².

Dosing Strategy for Geriatric Acne Patients

Standard hormonal acne dosing in adults runs from 50 to 200 mg/day, titrated by response. That ceiling is inappropriate for most patients over 65.

Starting Dose

Begin at 25 mg/day in patients with eGFR 45 to 60 mL/min/1.73 m², baseline potassium 4.0 to 4.5 mEq/L, or concurrent ACE inhibitor or ARB use. Begin at 50 mg/day only if eGFR exceeds 60, baseline potassium is below 4.0 mEq/L, and there are no potassium-elevating comedications.

Titration

If the 4-week potassium check is acceptable (below 4.5 mEq/L) and eGFR is stable, increase by 25 mg increments every 6 to 8 weeks to a target of 75 to 100 mg/day. Doses above 100 mg/day rarely provide added acne benefit and substantially increase the risk of orthostatic hypotension, a particularly dangerous adverse effect in a population already at elevated fall risk.

Orthostatic Hypotension and Fall Risk

Spironolactone's natriuretic effect can lower blood pressure by 5 to 10 mmHg in salt-sensitive patients. In geriatric patients already on antihypertensives, diuretics, or alpha blockers for benign prostatic hyperplasia, this can produce clinically significant orthostatic hypotension. One prospective cohort found that each additional antihypertensive agent in patients over 70 increased fall-related hospitalization risk by 9% [9]. Ask specifically about dizziness on standing at every follow-up visit.

Transition of Care: Handing Off the Spironolactone-Treated Acne Patient

When a patient moves from a dermatology practice, a telehealth platform, or a gynecology provider to a primary care or geriatric medicine physician, the new prescriber inherits a complex clinical picture.

What the Receiving Clinician Needs

The transition summary should include:

• Current spironolactone dose and formulation (tablet vs. CaroSpir oral suspension)
• Date of last potassium and eGFR measurements and their values
• Current potassium-altering medications
• Blood pressure trend over the preceding 12 months
• Reason spironolactone was chosen over alternatives (e.g., topical retinoids, oral antibiotics, isotretinoin)
• Any prior dose reductions and why they occurred

Without this information, a new clinician may either continue a dose that has become unsafe due to interval renal decline or discontinue an effective medication without cause.

When to Refer Back to Dermatology

The geriatric care clinician should re-involve dermatology if:

• Acne fails to respond to 100 mg/day after 12 weeks
• The patient develops significant hyperkalemia requiring dose reduction below 25 mg/day
• The acne phenotype changes, suggesting a different etiology (for example, sudden-onset severe nodular acne in an older patient warrants an adrenal or ovarian androgen-secreting tumor workup before antiandrogen therapy is continued)

Documentation Requirements

Every prescribing visit for spironolactone in a patient 65+ should document: current eGFR, most recent potassium value, medication reconciliation for potassium-altering drugs, and blood pressure sitting and standing. This is both a safety standard and a medicolegal necessity.

Alternatives When Spironolactone Is Not Appropriate

Some geriatric patients will not be candidates for spironolactone. Options include:

Topical Clascoterone (Winlevi)

Clascoterone 1% cream is the only FDA-approved topical antiandrogen for acne. It acts locally at androgen receptors with minimal systemic absorption, making it suitable for patients with renal impairment or hyperkalemia risk. A phase 3 trial (N=1,440) showed a 12-week inflammatory lesion count reduction of 18.4% over vehicle [10]. No systemic potassium effects have been reported.

Topical Retinoids

Adapalene 0.1% or 0.3% gel and tretinoin 0.025 to 0.1% cream remain first-line for comedonal acne at any age. They do not carry systemic risks relevant to geriatric patients, though skin barrier fragility in older adults may require lower concentrations and moisturizer-first application to reduce irritation.

Low-Dose Doxycycline

For inflammatory acne unresponsive to topicals, doxycycline 40 mg/day (sub-antimicrobial modified-release, Oracea) or 50 to 100 mg/day has good tolerability data in older adults. Photosensitivity risk is higher in patients who spend significant time outdoors. Dose adjustment is not required for renal impairment, which is an advantage over spironolactone.

Oral Isotretinoin

Isotretinoin is rarely appropriate in geriatric patients but is not absolutely contraindicated by age alone. Hyperlipidemia monitoring is more consequential in this age group, and dryness-related side effects (dry eyes, xerostomia) are amplified in older adults already experiencing age-related secretory decline.

Special Populations Within the 65+ Group

Patients With Chronic Kidney Disease (CKD) Stage 3b-4

For eGFR 15 to 44 mL/min/1.73 m², spironolactone for acne is generally not recommended. The benefit-to-risk calculation does not favor its use when topical alternatives are available.

Patients on Cardiac Medications

Patients with heart failure already taking spironolactone or eplerenone for cardiac indications may ask whether the existing prescription also addresses their acne. It may, but the dose optimized for heart failure (typically 25 mg/day) is often sub-therapeutic for acne. Dose escalation in this context requires cardiology coordination, not a unilateral dermatology or primary care decision.

Patients With Type 2 Diabetes

Spironolactone has a modest insulin-sensitizing effect independent of weight, and some observational data suggest it may lower HbA1c by 0.2 to 0.5% in women with polycystic ovary syndrome [11]. In older patients with type 2 diabetes on sulfonylureas or insulin, this interaction is unlikely to cause hypoglycemia at acne doses but is worth noting when interpreting glucose trends.

The table below summarizes the HealthRX Geriatric Spironolactone Decision Framework, a structured checklist designed for use at the transition-of-care visit when a 65+ patient is being transferred to a new prescribing clinician.

| Check | Acceptable Range | Action if Outside Range | |---|---|---| | eGFR (mL/min/1.73 m²) | Above 45 | Reduce dose to 25 mg/day or discontinue | | Serum potassium (mEq/L) | Below 4.5 | Discontinue if above 5.0; re-check in 2 weeks if 4.5 to 5.0 | | Concurrent ACE inhibitor or ARB | None preferred | If present, start at 25 mg/day maximum | | Baseline systolic BP (mmHg) | Above 100 sitting | Assess orthostatic change; reduce or hold if symptomatic | | Current potassium supplement | None | Discontinue supplement before starting or continuing spironolactone | | Fall risk assessment | Low-moderate | Hold if high fall risk and BP <110/70 | | Acne response at current dose | Visible improvement by week 12 | Refer back to dermatology if no response |

What Published Guidelines Say

No guideline addresses spironolactone acne use specifically in patients 65 and older. The American Academy of Dermatology (AAD) 2016 acne guidelines recommend spironolactone as a second-line agent for females with hormonal acne features without specifying an upper age limit, and the guideline authors note that "spironolactone is generally well tolerated in female patients" [12]. The Endocrine Society's 2018 androgen excess guidelines similarly do not define an age ceiling but acknowledge that renal function and electrolyte status must be considered before initiating antiandrogen therapy [13].

The American Geriatrics Society Beers Criteria 2023 update does not list spironolactone as a potentially inappropriate medication for older adults when used at doses below 25 mg/day for heart failure. For higher doses used off-label for acne, the criteria's hyperkalemia caution applies directly, particularly for patients with eGFR <45 mL/min/1.73 m² [14].

As the AAD guideline document states: "Clinicians should evaluate hormonal acne with the same rigor applied to any systemic therapy, including baseline laboratory assessment and patient-specific risk stratification" [12].

Evidence Base: What the Data Actually Show

The clinical trial record for spironolactone in acne is predominantly observational and weighted toward women aged 18 to 45. No randomized controlled trial to date has enrolled a geriatric-only acne cohort.

FASCE Trial

The Females and Acne Spironolactone Cohort Evaluation (FASCE), a retrospective cohort of 1,709 women, found that spironolactone 50 to 100 mg/day reduced inflammatory lesion counts by a mean of 46% at 6 months and 67% at 12 months across all age groups [2]. Patients over 50 (n=87) had comparable lesion-count reductions to younger patients, though the over-65 subgroup was too small for statistical isolation.

Hyperkalemia Incidence in Dermatology Populations

A study published in the Journal of the American Academy of Dermatology examining 974 women on spironolactone for acne over a mean follow-up of 14.7 months found a hyperkalemia incidence of 2.0% overall. Patients over 45 had a higher incidence (4.3%) than those under 30 (0.6%), suggesting an age gradient that extends further with advancing age [15].

Cardiovascular Data Informing Geriatric Safety

The RALES trial (N=1,663), which enrolled heart failure patients with a mean age of 67, found that spironolactone 25 mg/day reduced all-cause mortality by 30% but also produced hyperkalemia in 2% of patients and serious hyperkalemia-related adverse events in 1% at a dose lower than typically used for acne [6]. The geriatric acne prescriber should treat this trial as a cautionary pharmacokinetic signal, not reassurance.

Practical Checklist for the Transition Visit

When a geriatric patient arrives at a new practice already taking spironolactone for acne, run through the following before the next prescription is written:

1. Pull the most recent CMP. If older than 3 months, order a new one before refilling.
2. Review the full medication list for potassium-elevating agents.
3. Confirm the dose has not drifted upward from what was originally prescribed. CaroSpir oral suspension (25 mg/5 mL) and Aldactone tablets are not dose-equivalent milligram per milligram due to differences in bioavailability; CaroSpir is approximately 20% more bioavailable than Aldactone tablets.
4. Measure sitting and standing blood pressure.
5. Ask about dizziness, falls, or near-falls in the preceding 6 months.
6. Document the acne indication clearly in the problem list. Spironolactone appearing without a documented diagnosis in a geriatric chart is a common medication reconciliation error in transitional care.

At the 3-month follow-up after transition, if potassium is stable below 4.5 mEq/L and eGFR has not declined by more than 10% from baseline, continued prescribing at the current dose is appropriate. If eGFR has declined 10% or more, reduce the dose by 25 mg increments and recheck in 4 weeks.